Experimental ALS drug RJK002 enters first human safety trial
NCT ID NCT06493279
First seen Nov 20, 2025 · Last updated May 09, 2026 · Updated 22 times
Summary
This early-stage study tests whether a single injection of RJK002 into the spinal fluid is safe for people with ALS, a progressive nerve disease. Nine adults with ALS will receive the drug and be monitored for side effects and changes in daily function. The goal is to find a safe dose for future studies, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Third Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.